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Abstract: The immunological mechanism underlying Immunoglobuline E (IgE)-mediated cow’s milk
allergy has been subject to investigations for many years. Identification of the key immune cells
(mast cells, B cells) and molecules (IgE) in the allergic process has led to the understanding that
avoidance of IgE-crosslinking epitopes is effective in the reduction of allergic symptoms but it cannot
be envisioned as a treatment. For the treatment and prevention of IgE-mediated cow’s milk allergy, it
is thought that the induction of a sustained state of immunological tolerance is needed. In this review,
we will discuss various approaches aimed at achieving immunological tolerance and their success.
Furthermore, we will speculate on the involved immunological mechanism.
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1. Immunological Aspects of Cow’s Milk Allergy
Of all known food allergies in infancy, cow’s milk allergy (CMA) is of special interest to
immunologists as most allergic infants will acquire spontaneous tolerance toward cow’s milk before
the age of 3 years. A Danish birth cohort showed that children with confirmed cow’s milk allergy
appeared to be tolerant in 56% and 77% of the children at age 1 and 2 years, respectively [1,2]. While
the incidence of cow’s milk allergy is estimated to be around 2–3%, less than 0.5% of adults suffer
from CMA [3]. Ingestion of cow’s milk can lead to acute cutaneous symptoms, such as urticaria, and
may also lead to immediate-type pulmonary and/or gastro-intestinal symptoms or, especially at older
ages, systemic anaphylaxis [4]. Therefore, there is a need for proper allergy management during the
“allergic” years and, in addition, options to accelerate the process of tolerance acquisition would be
welcomed by affected families. Besides allergic infants, there is also a population of adults displaying
Immunoglobuline E (IgE)-mediated cow’s milk allergy [5]. Cow’s milk protein (CMP) contains various
proteins, of which the whey proteins—β-lactoglobulin and α-lactalbumin, and the caseins (αs1-,
αs2-, β-, and κ-casein)—are the most important proteins regarding allergy. Specific IgE antibodies
to all the subfractions of both casein and whey proteins can be detected in infants and children with
CMA [5]. Besides B cell activity markers, such as IgE antibodies, T cell activity toward the various
cow’s milk proteins (both whey proteins and caseins) can also be found. Of interest, CM-specific T
cells can be isolated from both allergic and non-allergic individuals [6]. Upon T cell activation, the
cytokine profile of a T cell will influence the subsequent B cell responses. B cells will class switch their
immunoglobulin production under the influence of T-cell-derived cytokines. T-cell-derived Interleukin
(IL)-4 production will cause the process of Ig class switching of B cells toward IgE (causing sensitization
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and subsequent allergy after exposure to the specific allergen), whereas IL-10 promotes the production
of Immunoglobuline G4 (IgG4) (possibly involved in the process of immune tolerance). It has been
demonstrated that cow’s-milk-specific IgG4 is linked to tolerance in children with increased levels of
IgE [7,8]. However, there is still a scientific debate whether increased IgG4 might be just an indicator
for increased/high exposure. Therefore, the preceding T cell response in cow’s-milk-allergic individuals
will have a large impact on the immune response toward the proteins in cow’s milk, and thereby, the
skewing towards an allergic or a tolerogenic response. T cells recognize specific parts of proteins (so
called T cell epitopes) only when presented by antigen-presenting cells in the context of an human
leucocyte antigen (HLA) molecule. Due to the large variation in genetic profiles between individuals
(variation in HLA genotype), many different T cell epitopes may induce an immune response. Within
some of the cow’s milk proteins, several dominant antigenic regions have been identified. For example,
within αs1-casein and β-lactoglobulin, T cell epitopes have been identified [9,10]. Since these T cell
epitopes appear to be recognized by T cells of both allergic and non-allergic donors, this suggests that
these parts of the protein may potentially be involved in the process of tolerance induction.
Importantly, the size of major histocompatibility complex (MHC) class II presented peptides is
only 15–24 amino acids (aa) long, while the size of a protein that can crosslink IgE on mast cells or
basophils is much larger, about 5–25 nm [11]. Therefore, as the T cell epitopes have the potential to steer
the immune response without causing the detrimental process of IgE crosslinking on mast cells and/or
basophils causing the allergic reaction, active immunotherapy using T cell epitopes/peptides may
be an attractive option for cow’s-milk-allergic patients (both as a preventive as well as a therapeutic
approach). One of the challenges is to identify enough diverse numbers of T cell epitopes, which
are recognized by the majority of the target population, in order to provide enough stimulation of
the immune system and to “re-train” the immune system away from an allergic response toward a
tolerogenic response. As mentioned earlier, the HLA genotype diversity of the population will be
of importance in the design of the diversity of the peptide mix needed to induce tolerance, as was
demonstrated before for birch pollen allergens [12].
For αs1 and β caseins, it has been shown that the IgE binding epitopes are more in the 3D
configuration in young children, whereas in adolescents and adults, it is more the linear structure that
is recognized [13,14]. Remarkably, this was not the case for the IgG binding epitopes [14]. This might
be related to the more immature digestive tract in young children, in which, for instance, the pH of the
stomach is somewhat higher than later in life, leaving the more 3D configuration intact [15].
2. Cow’s Milk Formula, Including Hydrolysate in Cow’s-Milk-Allergic Patients
For infants that cannot be breastfed, other nutritional solutions (in the form of formula) are available.
Several different cow’s-milk-protein-based formula are currently on the market, varying from a formula
based on whole cow’s milk protein (CMP), partially hydrolyzed CMP, to extensively hydrolyzed CMP,
and even amino-acid-based formulas. Extensively hydrolyzed cow’s milk formulas with documented
hypoallergenicity are being recommended as a first-choice formula for cow’s-milk-allergic infants and
young children [16,17]. It must be realized that this is mostly management, but not a cure, of the disease;
therefore, in the future, interventions are needed that aim at preventing or curing CMA. For prevention,
tolerance inducing partially hydrolyzed formulas have been developed for their potential to reduce
the risk of CMA since these formulas contain peptides of a specific length. So far, contradictory results
have been reported on the effect of these formulas on prevention. The largest individual study so
far did find a lower risk on allergic manifestations, but in a recent meta-analysis, no evidence for a
reduction in allergic manifestations (including CMA) was shown [18].
Factors, such as the selection of subjects, set up of study, type of product (hydrolysis degree, type
of hydrolyzed cow’s milk protein), and studies performed in small groups of patients, could play a role
in the observed discrepancies between studies. Furthermore, since the incidence of IgE-mediated CMA
is low, and spontaneous tolerance occurrence is relatively high, a preventive study with a primary
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outcome on CMA (instead of all allergic manifestations) would be important but very challenging
to conduct.
Recently, different commercially available infant formulas (intact proteins versus partially
hydrolyzed versus extensively hydrolyzed) were investigated on their in vitro immune profile. Not all
extensively hydrolyzed formulas reacted in a similar way with respect to IgE reactivity, proliferative
responses of immune cells, and cytokine profiles [19]. This was also true for the partial hydrolysates.
Direct comparison of in vivo reactivity of the hypoallergenic formulas in an at risk population and/or
in CMA patients with immune profiles in these target groups is currently lacking in the literature,
but would be needed to investigate whether in vitro profiles can explain the potential differences in
effectiveness mechanistically.
By comparing the immune response toward whole protein cow’s milk formulas versus partial and
extensive hydrolysates, it has been demonstrated that hydrolyzation of proteins reduces allergenicity
whilst maintaining immunogenicity (T cell reactivity), depending on the type of hydrolysate [20,21].
However, the degree of hydrolysis not only corresponds to reduced allergenicity, it may also lead to
reduced or different T cell reactivity [20,21]. The discrepancy between T cell activation profiles in these
studies may be explained by different patient populations included in these studies. The serum and T
cells used in the two studies were derived from cow’s-milk-allergic children [20] or adults [21], which
may have an important impact on IgE binding to conformational versus linear epitopes [13,14]. As the
cytokine profile is essential for the subsequent immunological processes, it is important to analyze the
capacity of the different T cell epitopes in the different cow’s-milk-based formulas with regard to their
immunostimulatory capacity.
Another important approach is to consider unprocessed, raw cow’s milk instead of the
commercially available heated and processed cow’s milk. Epidemiological data indicate that
consumption of raw milk in the first year of life protects against allergies, including asthma [22].
There are several potent immunomodulating activities in milk that are lost during processing, such
as transforming growth factor Bèta (TGF-β), IL-10, vitamin D, and lactoferrin, as well as fatty acids,
oligosaccharides, and lipids, some of which are lost during processing [23]. Importantly, these bovine
products have potent interspecies effects on human cells. However, although there are several potential
advantages to introducing raw milk into the diet of young children, there is a significant risk of
bacterial infections that also hampers controlled studies in infants to prove its effect [24]. Therefore,
minimal processing techniques of raw milk to preserve the immunomodulating activity but safeguard
the microbiological quality are needed. Alternatively, isolating the immune factors that drive the
protective effects and provide these isolated components to infants is an interesting way to go.
Additionally, the composition of the intestinal microbiota might influence the immune response
toward cow’s milk proteins (and the different T cell epitopes). Since it has been shown that the
composition of the microbiota affects the development of the mucosal immune system, it is highly
likely that differences in microbiota will shape the microenvironment in which the immune response is
elicited [25]. Indeed, the microbiome of atopic versus healthy infants was shown to be different, and with
specific pre- and/or probiotics, this dysbiosis may be altered toward a beneficial microenvironment in
which tolerance toward cow’s milk proteins can be induced [26]. Interestingly, combining an extensively
hydrolyzed formula with a probiotic strain may further accelerate tolerance development [27].
3. Baked Milk in the Treatment of Cow’s Milk Allergy
It has been suggested that the introduction of baked milk into the diet of the child may speed up
the resolution of cow’s milk allergy [28]. Most children outgrow their cow’s milk allergy by the age of
3 years old [29]. These individuals with transient cow’s milk allergy produce IgE antibodies that are
primarily directed at conformational epitopes. Since high temperatures (baking) reduce allergenicity by
destroying these epitopes, the hypothesis is that the transient allergic group of children would tolerate
baked milk products. More importantly, the addition of baked-milk products to the diet of these
children appears to markedly accelerate the development of tolerance to unheated milk compared to a
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strict avoidance diet, which is currently the “standard of care” [28]. This approach is being introduced
into clinical practice, although the hard evidence to underpin it seems to be lacking.
In a recent systematic review by Lambert et al. to examine the evidence as to whether baked milk
introduction into the diet leads to a larger proportion of children outgrowing their milk allergy, only
three studies could be included [30]. Although the results are promising, e.g., baked milk was found to
be well tolerated in children and no serious adverse reactions were reported, without randomization
of the intervention, these studies are at a major risk of confounding by factors that are not equally
distributed between the different groups.
Nevertheless, introduction of baked milk into the diet can also increase the quality of life by
expanding the diet, boosting nutrition, and promoting participating in social activities [31].
The study of potential biomarkers to predict the tolerability of baked milk, such as allergen-specific
IgE or the skin prick test (SPT), are ongoing. A cow’s-milk-specific IgE level≥15 KUA/L and SPT ≥8 mm
in children ≤2 years old are highly predictive for a positive oral challenge reaction with baked milk [32].
Using specific IgG4 levels in addition to specific IgE levels may help predict baked milk reactivity. Casein
and beta-lactoglobulin-specific IgE/IgG4 ratios appear to be significantly higher in baked-milk-reactive
subjects compared to baked-milk-tolerant subjects [33].
Although there are currently no results of randomized controlled studies to determine whether
baked milk speeds up the resolution of cow’s milk allergy, the opportunity to reduce the child’s dietary
restrictions can potentially have a major beneficial effect on the food allergic child and their family.
4. Allergen Immunotherapy in the Treatment of Cow’s Milk Allergy
A more direct approach to reach tolerance in the cow’s milk allergic patients is via allergen
immunotherapy (AIT), in which cow’s milk is administered for a longer period, starting with
micrograms, increasing to milligrams, and finally to grams via either the oral route, including
sublingual administration [34], or epicutaneous route [35]. Each of these approaches is intended to
induce some level of desensitization with repeated exposure to the allergenic food protein, although the
risks and potential benefits of each treatment differ significantly [36]. Permanent tolerance is defined
as the ability to ingest food without symptoms despite prolonged periods of avoidance or irregular
intake [37]. Both intact cow’s milk, as well as partially hydrolyzed cow’s milk, has been tested. In a
meta-analysis, it was shown that the relative risk for desensitization after allergen immunotherapy
(AIT) for cow’s milk was 0.12, 95% CI = 0.06–0.25 [34]. At the same time, the safety of AIT is an issue
and side effects are found frequently, though merely local [38]. Individual studies have evaluated the
immunological parameters changed by AIT. After the treatment with partially hydrolyzed formula of
cow’s-milk-allergic children and young adults (age range 1–20), a slight reduction in casein-specific
IgE was demonstrated after 16 weeks, but no increased concentrations of IgG4, nor changes in
casein-induced basophil degranulation [39]. In a younger group (7–12 months) treated with increasing
cow’s milk concentrations, cow’s-milk-specific IgG4 increased 20–40-fold, while IgE decreased about
2-fold [8]. In a cohort of 2-year-old children, AIT strongly reduced the skin reactivity for cow’s milk
and slightly increased (3-fold) the specific IgE concentrations for caseins and total cow’s milk [40].
Comparable levels of IgE decrease and IgG4 increase were noted in a study with older children
(5–15 years). However, only casein-specific IgE decreased, but not IgE levels for α-lactalbumin and
β-lactoglobulin [41]. Overall, even with the limited number of controlled studies, it seems that the
ratio of specific IgE/IgG4 decreased, mostly by the increased amounts of IgG4. The clinical benefit of
AIT in cow’s-milk-allergic patients is difficult to interpret, because this is only performed at a young
age in which the incidence of spontaneous tolerance is significant [1]. Moreover, whereas the adult
population needs a solution for cow’s milk allergy (CMA), there are no controlled studies performed
with AIT in this age group and is therefore is not recommended in adults [38].
One of the challenges in the AIT for cow’s milk allergy is that clinical tolerance only remains
when AIT is continued [34]. In contrast to AIT for insect venoms or pollen allergens, clinical tolerance
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to food allergens is lost rapidly after stopping the AIT procedure. The future challenge is therefore to
induce sustained clinical tolerance after AIT is stopped.
5. Which Immune Cells Are Involved in Immunotherapy for Cow’s Milk Allergy?
To gain insight in the immunological mechanism of tolerance induction, the analysis of various
immune cells possibly involved in this process is of high interest. In Figure 1, we have depicted three
subsets that we would like to highlight, namely regulatory T-cells (Tregs), regulatory B-cells (Bregs),
and innate lymphoid regulatory cells (ILCregs). Tregs are cells with a strong regulatory capacity and
are generally referred to as the CD4+CD25+ regulatory T cell subset. In cow’s milk allergic adults,
it has been demonstrated that the percentage and function of CD4+CD25+ Tregs is intact [42]. Also,
in cow’s-milk-allergic children, the presence of Tregs has been investigated. A study by Savilahti et
al. showed that in the peripheral blood of allergic children, CD4+CD25+ Tregs can be detected and
are functionally active [43]. Therefore, specific immunotherapies aiming at the stimulation of these
naturally occurring regulatory T cells may contribute to the re-establishment of clinical tolerance in a
sustainable way in allergic individuals.
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One of the mechanisms by which CD4+CD25+ (Tregs) may enhance the process of tolerance
induction is via t e production of the suppressive cytokine IL-10. Results from a study investigating
the cow’s-milk-specifi T cell response in allergic children, which are tolerant to cow’s milk, show that
their cow’s-milk-specific T cell response is dominated by the producti n of large amounts of IL-10 [44].
T is sugge ts a ey role for IL-10-producing T cells in a long-lasting tolerogenic reaction i individuals
where the immune system is skewed toward a allergic phenotype. Another potential source of IL-10
is the subset of regulatory innate lymphoid c lls. ILC egs h v been recently described to be present in
the gut and produce IL-10 and TGF-β upon pathogenic stimulation, thereby p omoting a tolerogenic
nvironment [45]. Although a direct suppressive effect of ILCregs on ILC2 cells, which produce IL-4
and have been shown to pro ote food allergy by enhancing mast cell activati n and the disruption of
Treg functi n [46] has not been demon trated, the ILCreg-me iated production of IL-10 may play a
role in the proce s of tolerance ind ction by affecting other im une cells.
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For B cells, it has been suggested that a subpopulation, called regulatory B cells (Bregs),
is of importance for the induction and maintenance of tolerance to many different self- and
non-self-antigens [47]. Whether Bregs play a role in CMA remains to be established.
6. Conclusions
Important aspects to keep in mind when evaluating the different options for allergy prevention and
the treatment of cow’s-milk-allergic individuals are the intended target population (infants, children, or
adults) and the patient characteristics (IgE and IgG4 serum levels, SPT values). A better immunological
understanding of the mechanism underlying a sustained tolerance development in cow’s-milk-allergic
patients will aid in improving current therapies or developing new therapies.
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